Australien - Englisch - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

energique, inc. - calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - unii:18e7415pxq), croton tiglium seed (unii: 0hk2gzk66e) (croton tiglium seed - unii:0hk2gzk66e), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), plantago major (unii: w2469wno6u) (plantago major - unii:w2469wno6u), toxicodendron pubescens leaf (unii: 6io182rp7a) (toxicodendron pubescens leaf - unii:6io182rp7a), smilax regelii root (unii: 2h1576d5wg) (sarsaparilla - unii:2h1576d5wg) - calendula officinalis flowering top 12 [hp_x] in 1 ml - may temporarily relieve pain due to inflammation caused by but not limited to the following: itching and sensitivity, eruptions, blisters.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. may temporarily relieve pain due to inflammation caused by but not limited to the following: itching and sensitivity, eruptions, blisters.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; sodium lauryl sulfate; ethylcellulose; polysorbate 80; magnesium stearate; hyprolose; purified talc; iron oxide yellow; povidone; light magnesium oxide; propylene glycol; titanium dioxide - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 2 mg - foam - excipient ingredients: propylene glycol; purified water; emulsifying wax; cetyl alcohol; citric acid monohydrate; disodium edetate; butane; isobutane; propane; steareth-10 - budenofalk foam is indicated in the treatment of active rectal and rectosigmoid disease in ulcerative colitis.

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - methotrexate - oral tablet - 10mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - methotrexate - oral tablet - 2.5mg

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - hydrocortisone acetate, quantity: 10 % w/w - enema - excipient ingredients: cetyl alcohol; emulsifying wax; methyl hydroxybenzoate; propyl hydroxybenzoate; steareth-10; propylene glycol; trolamine; purified water; propane; isobutane - this product approved for registraiton as a variation of a product accepted for inclusion in the artg as 'currently supplied' at the commencement of the act. indications are held in artg paper records. previous product number aust r 15654. product information not reviewed. indications as at 21 august 1998: topical treatment of inflammation occurring in the rectal mucosa, eg ulcerative colitis, proctosigmoiditis and granular proctitis.

Europäische Union - Englisch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosuppressants - please refer to section 4.1 of the summary of product characteristics in the product information document.,

Europäische Union - Englisch - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - spondylitis, ankylosing; hidradenitis suppurativa; psoriasis; arthritis, juvenile rheumatoid; uveitis - immunosuppressants - rheumatoid arthritishefiya in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.hefiya can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis hefiya in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hefiya can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). adalimumab has not been studied in patients aged less than 2 years.enthesitis-related arthritis hefiya is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).axial spondyloarthritisankylosing spondylitis (as) hefiya is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.axial spondyloarthritis without radiographic evidence of as hefiya is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.psoriatic arthritishefiya is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.psoriasishefiya is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.paediatric plaque psoriasishefiya is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.paediatric plaque psoriasishefiya is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.hidradenitis suppurativa (hs)hefiya is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy.crohn’s diseasehefiya is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.paediatric crohn's diseasehefiya is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.paediatric ulcerative colitishefiya is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitis hefiya is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis hefiya is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis hefiya is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 500 mg - tablet, modified release - excipient ingredients: purified talc; ethylcellulose; povidone; microcrystalline cellulose; magnesium stearate - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.